Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug ...

The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term ...

Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

Arcus Biosciences (NYSE: RCUS) is setting the stage for a high-stakes Phase III showdown in kidney cancer, after early ...

Merck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial.

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

Merck (MRK) stock falls as the company withdraws U.S. marketing application for lung cancer therapy HER3-DXd developed with ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD1 and VEGF, following ...

Postoperative nivolumab added to standard-of-care adjuvant cisplatin radiotherapy “represents a potential new standard.” ...